Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective Observation of Cardiac Safety With Proteasome Inhibition

Trial Profile

Prospective Observation of Cardiac Safety With Proteasome Inhibition

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Carfilzomib (Primary)
  • Indications Heart failure; Multiple myeloma
  • Focus Adverse reactions
  • Acronyms PROTECT
  • Most Recent Events

    • 10 Sep 2019 Planned End Date changed from 1 Feb 2020 to 1 Feb 2022.
    • 10 Sep 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Feb 2020.
    • 12 Jun 2019 Results assessing incidence of Cardiovascular adverse events in patients with multiple myeloma receiving proteasome inhibitor therapy published in the Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top